Stock Trading Ideas

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

China Accounts Smaller Share In Nike Sales Compared To Pre-Pandemic Levels, But Tariff Pressure Still Persists: Analyst

What Is The Tariff Risk For Procter & Gamble? Analyst Calculates, Trims Outlook

China Accounts Smaller Share In Nike Sales Compared To Pre-Pandemic Levels, But Tariff Pressure Still Persists: Analyst

What Is The Tariff Risk For Procter & Gamble? Analyst Calculates, Trims Outlook

Analyst Upgrades Dow, Calls Capex Cut And Asset Sales Positive

Oil Drops Below Key Support: Is $55 The Next Stop For West Texas Intermediate?

Analyst Upgrades Dow, Calls Capex Cut And Asset Sales Positive

Oil Drops Below Key Support: Is $55 The Next Stop For West Texas Intermediate?

T-Mobile Beats Estimates, But Customer Growth Leaves Investors Wanting More, Says Analyst

Intel Shares Slide As Tariff Jitters Cloud Outlook, Analysts See More Challenges Despite New CEO Initiatives

Trading Ideas Recent News

Charter Communications Stock Rises 3.6% After Key Signal

A significant trading signal occurred for Charter Communications at $361.02, after which CHTR rose up to 3.6%.

Comcast Faces Analyst Concerns Over Broadband Losses Despite Revenue And Peacock Gains

Rosenblatt analyst maintains Neutral rating on Comcast (CMCSA) due to subscriber loss, despite upside in revenues and EBITDA in Q1 earnings.

Mobileye's Robotaxi Push Gains Speed With Uber And Lyft, But Analyst Cuts 2026 Forecast On Tariff-Led SuperVision Delays

Mobileye stock rises as analyst highlights robotaxi momentum with Uber and Lyft, but trims 2026 forecast on SuperVision delays tied to tariffs.

Alphabet Analysts Say AI Opportunity Not Reflected In Stock Price, Welcome Break Up Attempts: 'GOOGL Is Worth More In Pieces'

Analysts see strength from Alphabet's key segments like search, cloud and YouTube, with AI starting to show more monetization opportunities.

Trade Deal Or No, These 2 Stocks Will Outperform

What's Going On With Summit Therapeutics Stock On Friday?

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials.

Coursera AI Strategy Wins Points With Analyst, But Market Jitters Linger

Coursera shares jump as JPMorgan lifts price target, citing strong AI-driven initiatives but urging consistent execution for future growth.

PepsiCo Posts In-Line Results As Guidance Reflects Tariff Costs, Analysts Say

PepsiCo (PEP) shares plunged after reporting Q1 sales decline amid exciting earnings season. Key analyst takeaways include lowered guidance due to tariffs.

Swiss Franc Soars As Trump Tariffs Spark US Volatility

Union Pacific Analysts Cut Their Forecasts After Downbeat Results

Crude Oil Edges Higher; Phillips 66 Posts Wider-Than-Expected Loss

Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift

Avantor matched EPS expectations but missed revenue targets and cut its outlook as its CEO steps down and cost-saving plans ramp up.

Bezos Vs. Tesla Vs. Rivian Stock? Company Backed By Amazon Founder Can Turn $20K EV Truck Into SUV

Rivian and Tesla might have another viable competitor in the EV space, with a Jeff Bezos-backed company.